Moleculin, LLC   Report issue

For profit Phase 1 Phase 2
Founded: Houston TX United States (2006)

Organization Overview

First Clinical Trial
2013
NCT01826201
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Moleculin Biotech, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

cytarabine (cytosar-u) (1 trial)

liposomal annamycin (4 trials)

mol4239 (1 trial)

wp1066 (1 trial)

Drugs in Phase 1 Trials (2)

wp1122 (1 trial)

wp1220 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 6